Research Focus

Research and Technology Management; Research Project Manager

Recent additions – View all

1. Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: Phase 3 CALGB 80802 randomized clinical trial

   Journal Article

   Abou-Alfa, G. K.; Shi, Q.; Knox, J. J.; Kaubisch, A.; Niedzwiecki, D.; Posey, J.; Tan, B. R. Jr; Kavan, P.; Goel, R.; Lammers, P. E.; more...
   JAMA Oncology (2019)

   Fulltext@MSK | Save
2. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)

   Meeting Abstract

   Abou-Alfa, G. K.; Niedzwieski, D.; Knox, J. J.; Kaubisch, A.; Posey, J.; Tan, B. R.; Kavan, P.; Goel, R.; Lammers, P. E.; Bekaii-Saab, T. S.; more...
   Journal of Clinical Oncology (2016)

   Fulltext@MSK | Save
3. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)

   Meeting Abstract

   Abou-Alfa, G. K.; Niedzwieski, D.; Knox, J. J.; Kaubisch, A.; Posey, J.; Tan, B. R.; Kavan, P.; Goel, R.; Murray, J. J.; Bekaii-Saab, T. S.; more...
   Journal of Clinical Oncology (2016)

   Fulltext@MSK | Save